Related Experiment Video
Updated: Mar 29, 2026
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
Published on: January 7, 2019
RGD-based Therapy: Principles of Selectivity
Mikhail A Rubtsov1, Marina S Syrkina, Gjumrakch Aliev
1Department of Molecular Biology, Faculty of Biology, Lomonosov Moscow State University, 119991, Leninskie Gory 1/b.12, Moscow, Russia. ma_rubtsov@mail.ru.
Abstract:
Design of selective anticancer drugs that are targeting RGD-binding integrin receptors which are known to be one of the perspective directions in the field of oncology. Significant progress in the development and application of these types compounds is already demonstrated. The accumulating body of basic and clinical evidence demonstrates potential significant effects on both in vitro and in vivo experimental models. However, the specific mechanism of action of these compounds is generally not a fully elucidated or the exact target responsible for the achievement of stated effects hasn't yet been defined sufficiently. To date eight types of integrin receptors, which are capable to recognize RGD-motif in natural ligands, has in fact been identified as (namely αIIbβ3, αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1). Even so, the estimation of the affinity of one particular RGD-bearing anticancer agent is often based on the determination of the binding efficacy to only one or rarely two integrin receptors. Traditionally the range of targets is restricted by the integrins, which are known to be highly expressed in a particular model system. While potential interactions of such an agent with other RGD-recognizing receptors usually remain beyond the research. Nonetheless, such interactions may also affect the viability and behavior of cancer cells. In this review we attempt to critically analyze the principles of selectivity achievement in the case of RGD-bearing natural ligands and the applicability of these principles in the context of the anticancer drug design.
Insights
Designing anticancer drugs targeting RGD-binding integrin receptors shows promise. However, understanding drug interactions with all eight RGD-recognizing integrins is crucial for effective cancer therapy.
Area of Science:
- Oncology
- Drug Discovery
- Molecular Biology
Background:
- Targeting RGD-binding integrin receptors is a promising strategy for selective anticancer drug development.
- While progress has been made, the precise mechanisms of action and specific targets for these drugs are not fully understood.
- Eight RGD-motif recognizing integrin receptors have been identified (αIIbβ3, αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1).
Purpose of the Study:
- To critically analyze the principles of selectivity in RGD-bearing natural ligands.
- To assess the applicability of these principles in designing novel anticancer drugs.
- To highlight the importance of considering interactions with multiple integrin receptors.
Main Methods:
- Literature review and critical analysis of existing research on RGD-binding integrins and anticancer agents.
- Examination of selectivity principles in natural ligands.
- Evaluation of current drug design strategies and their limitations.
Main Results:
- Current drug development often focuses on only one or two integrin targets, neglecting potential interactions with others.
- The broad range of RGD-recognizing integrins suggests complex interactions that influence drug efficacy.
- Understanding these interactions is key to improving drug selectivity and effectiveness.
Conclusions:
- Achieving selectivity in RGD-binding integrin-targeted anticancer drugs requires a comprehensive understanding of interactions with all relevant receptors.
- Future drug design should move beyond single-target approaches to encompass broader integrin engagement.
- Further research is needed to fully elucidate the mechanisms of action and optimize the design of these targeted therapies.
Related Concept Videos
01:25Dose-Response Relationship: Selectivity and Specificity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...